Sixfold will join the panel discussion on 'Delivery Carriers for Efficient siRNA Therapies', represented by Dr. Ioanna Mylonaki, Head of Preclinical R&D at Sixfold, on Wednesday, 20th of April, at 9:45 a.m. EDT.

Dr. Mylonaki will further coordinate the round table discussion on 'Effective Cell & Tissue Specificity for siRNA Therapeutics'.

Details on the program and participants of the 3rd RNAi-Based Therapeutics Summit can be found here.

Footnotes

Media contact:

Sixfold Bioscience

pr@sixfold.bio

Sixfold Bioscience is a venture-backed preclinical-stage biotechnology company, founded in 2017, based at the Translation & Innovation Hub in White City, London. Sixfold develops programmable drug delivery systems, with a current focus on short interfering RNA for gene silencing and messenger RNA for gene expression.

Sixfold’s RNA delivery platform, Mergo®, was conceived by co-founders Dr Perdrix Rosell and Dr George Foot, who were left frustrated by current delivery systems that were either too toxic or faced complex engineering challenges. The Company’s differentiated approach is based on engineering biocompatible nano-architectures with precise chemical profiles that guide the RNA to selected organs.